See more : Crank Media Inc (CRKM) Income Statement Analysis – Financial Results
Complete financial analysis of Connect Biopharma Holdings Limited (CNTB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Connect Biopharma Holdings Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Sunshine Capital Limited (SCL.BO) Income Statement Analysis – Financial Results
- SGD Holdings, Ltd. (SGDH) Income Statement Analysis – Financial Results
- PVA TePla AG (TPLKF) Income Statement Analysis – Financial Results
- Gores Metropoulos II, Inc. (GMIIU) Income Statement Analysis – Financial Results
- TOP MATERIAL Co., Ltd (360070.KQ) Income Statement Analysis – Financial Results
Connect Biopharma Holdings Limited (CNTB)
About Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 988.00K | 1.03M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -988.00K | -1.03M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 51.91M | 95.26M | 81.34M | 23.12M | 15.44M |
| General & Administrative | 14.52K | 20.37M | 19.23M | 7.31M | 1.41M |
| Selling & Marketing | 13.51M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.53M | 20.37M | 19.23M | 7.31M | 1.41M |
| Other Expenses | -4.35M | -940.31K | -2.98M | -1.07M | -411.44K |
| Operating Expenses | 62.07M | 114.69M | 97.59M | 29.36M | 16.44M |
| Cost & Expenses | 62.07M | 114.69M | 97.59M | 29.36M | 16.44M |
| Interest Income | 5.20K | 1.56M | 97.67K | 109.84K | 154.65K |
| Interest Expense | 0.00 | 21.03K | 6.91K | 6.43K | 7.69K |
| Depreciation & Amortization | 988.00K | 1.01M | 640.98K | 221.05K | 114.61K |
| EBITDA | -58.37M | -111.31M | -204.93M | -118.21M | -24.78M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -62.07M | -117.66M | -99.15M | -30.30M | -15.99M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.69M | -403.66K | -103.21M | -89.07M | -8.41M |
| Income Before Tax | -59.38M | -116.12M | -204.94M | -119.37M | -24.46M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 120.00K | 297.52K | 266.47K | 934.46K | -442.49K |
| Net Income | -59.50M | -116.42M | -205.21M | -120.30M | -24.02M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.08 | -14.50 | -25.00 | -14.45 | -3.02 |
| EPS Diluted | -1.08 | -14.50 | -25.00 | -14.45 | -3.02 |
| Weighted Avg Shares Out | 55.07M | 55.04M | 52.27M | 53.94M | 55.82M |
| Weighted Avg Shares Out (Dil) | 55.07M | 55.04M | 52.27M | 53.94M | 55.82M |
Attovia Therapeutics Appoints Chief Financial Officer
CNTB Stock Surges Over 5% Amid Strong Financial Performance
Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update
Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Connect Biopharma Announces New Leadership and Chair of the Board of Directors
Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
Source: https://incomestatements.info
Category: Stock Reports